N/A N=298 Mechanisms of Action and Outcome
Mental Disorders
Primary: Patient Activation — 29.12; 28.82; 29.21 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Ovarian Cancer
Primary: Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors…
Phase 2 N=24 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Acral Lentiginous Malignant Melanoma · Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size
Primary: Objective Tumor Response (Partial or Complete Response) According to RECIST — 0 participants
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 3 N=1,065 Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 78.4; 77.5; 16.6; 18.4…
Phase 4 N=24 Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
Epilepsy
Primary: MMSE at Baseline and at Three (3) Months. — 18.2; 2.2 units on a scale — p=.01
Phase 4 N=161 Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
Influenza
Primary: Percentage of Patients With Normal Body Temperature — 4; 1; 15; 15 Percentage of participants — p=0.05
Phase 2 N=42 Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid…
Phase 3 N=1,055 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 75; 80; 20.3; 14.9 Percentage…
Phase 3 N=235 Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 32.9; 84.9 Percentage of Participants
N/A N=64 Village Interactive Training and Learning Study
Aged
Primary: Bird Safari Subtest of PositScience Insight — 50.043; 50.292; 49.570; 43.218 T-score units — p=< .001
Phase 4 N=45 Premedication for Non-Emergency Endotracheal Intubation In the NICU
Respiratory Distress Syndrome
Primary: Present the Percentage of Participants With an Excellent Ease of Intubation Rating — 91; 17 % reported as excellent
N/A N=94 Cardiac Rehabilitation Peer Mentorship
Percutaneous Coronary Intervention · Coronary Artery Bypass Graft Surgery, With or Without Valve Surgery · Acute Coronary Syndrome
Primary: Cardiac Rehabilitation Enrollment — 20; 15 participants
N/A N=17 A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Hypertension · Plasma Renin Activity
Primary: Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic — 3; 1 participants
Phase 3 N=545 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33